GOLM1, CD24, PSCA, and the gene fusion TMPRSS2-ERG were selected as overexpressed mRNAs in prostate cancer, whereas ANXA3 and SLC45A3 were selected as underexpressed mRNAs in prostate cancer for evaluation. This evidence concerns the gene TMPRSS2 and prostate cancer.